| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Lypressin exerts its effects by binding to vasopressin receptors, which are analogous to human Vasopressin 2 (V2) receptors. These receptors are primarily located in the kidneys, where they play a crucial role in regulating water reabsorption and urine concentration. By activating these receptors, lypressin promotes water retention, which is essential for maintaining fluid balance. Additionally, lypressin can induce contraction of smooth muscle, particularly in the rabbit urinary bladder, and activate adenylyl cyclase, a key enzyme in signal transduction.
|
|---|---|
| ln Vitro |
In vitro, lypressin has been shown to induce contraction of rabbit bladder smooth muscle. This activity is mediated through its binding to vasopressin receptors and subsequent activation of intracellular signaling pathways. Lypressin also activates adenylyl cyclase, leading to increased levels of cyclic AMP (cAMP), which serves as a second messenger in various cellular processes. These in vitro activities make lypressin a valuable tool for studying receptor-mediated signaling and smooth muscle physiology.
|
| ln Vivo |
In vivo, lypressin is primarily used in medical applications to treat conditions such as diabetes insipidus, a disorder characterized by excessive urination and thirst due to a deficiency of antidiuretic hormone. It is also used to improve vasomotor function and blood pressure. Additionally, lypressin has been investigated for its potential therapeutic applications in hypotension and certain types of shock. By promoting water reabsorption and vasoconstriction, lypressin helps restore fluid balance and maintain blood pressure.
|
| Enzyme Assay |
In vitro receptor binding assays for lypressin typically involve the use of membrane preparations from cells expressing vasopressin receptors. Radiolabeled vasopressin or a specific ligand is displaced by increasing concentrations of lypressin to determine its binding affinity (Ki). Non-specific binding is determined in the presence of an excess of unlabeled ligand. These assays are crucial for characterizing the interaction between lypressin and its target receptors.
|
| Cell Assay |
Cell-based functional assays for lypressin involve treating cells expressing vasopressin receptors with the compound and measuring downstream signaling events. For example, the activation of adenylyl cyclase can be assessed by measuring the accumulation of cAMP in response to lypressin treatment. Additionally, calcium mobilization assays can be used to study receptor-mediated signaling pathways. These assays help elucidate the compound's mechanism of action and its effects on cellular function.
|
| Animal Protocol |
In vivo animal studies for lypressin typically involve administration to animal models of diabetes insipidus or hypotension. The compound's ability to promote water reabsorption, concentrate urine, and increase blood pressure is assessed. These studies are essential for evaluating the compound's therapeutic potential and for understanding its pharmacokinetic and pharmacodynamic properties.
|
| ADME/Pharmacokinetics |
Lypressin is a peptide hormone and, as such, is typically administered via injection due to its poor oral bioavailability. Following administration, it is rapidly distributed and metabolized. The compound's pharmacokinetic profile is characterized by a short half-life, requiring frequent dosing to maintain therapeutic levels. Its metabolism involves enzymatic degradation by peptidases.
|
| Toxicity/Toxicokinetics |
The toxicological profile of lypressin is generally consistent with that of other vasopressin analogues. Adverse effects may include gastrointestinal disturbances, headache, and allergic reactions. Due to its vasoconstrictive properties, caution is advised in patients with cardiovascular disease. The compound is contraindicated in patients with known hypersensitivity to vasopressin or its analogues.
|
| References |
|
| Additional Infomation |
(2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexane-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazoneeicosico-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide is a cyclic peptide.
Porcine antidiuretic hormone (vasopressin). It is a cyclic nonapeptide, differing from arginine vasopressin (ARG-VASOPRESSIN) only in one amino acid, specifically the 8th residue, which is lysine instead of arginine. Lysine vasopressin is used to treat diabetes insipidus or to improve vasomotor function and blood pressure. Lypressin (Lysine Vasopressin) is a synthetic analogue of the antidiuretic hormone vasopressin, used primarily for the treatment of diabetes insipidus. It is an endogenous antidiuretic hormone in the majority of mammalian species. Unlike arginine vasopressin (AVP), which is found in humans, lypressin contains lysine at position 8 instead of arginine. It is a strong vasopressor used to modulate blood pressure. The compound is released into the blood from nerve terminals in the posterior pituitary and median eminence. |
| Molecular Formula |
C46H65N13O12S2
|
|---|---|
| Molecular Weight |
1056.2182
|
| Exact Mass |
1055.431
|
| Elemental Analysis |
C, 52.31; H, 6.20; N, 17.24; O, 18.18; S, 6.07
|
| CAS # |
50-57-7
|
| Related CAS # |
Lysipressin acetate; 83968-49-4
|
| PubChem CID |
644076
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
1610.4±65.0 °C at 760 mmHg
|
| Flash Point |
927.7±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
-5.74
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
73
|
| Complexity |
1960
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
S1C([H])([H])C([H])(C(N2C([H])([H])C([H])([H])C([H])([H])[C@@]2([H])C(N([H])[C@]([H])(C(N([H])C([H])([H])C(N([H])[H])=O)=O)C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])=O)=O)N([H])C(C([H])(C([H])([H])C(N([H])[H])=O)N([H])C([C@]([H])(C([H])([H])C([H])([H])C(N([H])[H])=O)N([H])C([C@]([H])(C([H])([H])C2C([H])=C([H])C([H])=C([H])C=2[H])N([H])C(C([H])(C([H])([H])C2C([H])=C([H])C(=C([H])C=2[H])O[H])N([H])C([C@]([H])(C([H])([H])S1)N([H])[H])=O)=O)=O)=O)=O
|
| InChi Key |
BJFIDCADFRDPIO-DZCXQCEKSA-N
|
| InChi Code |
InChI=1S/C46H65N13O12S2/c47-17-5-4-9-29(40(65)52-22-38(51)63)54-45(70)35-10-6-18-59(35)46(71)34-24-73-72-23-28(48)39(64)55-31(20-26-11-13-27(60)14-12-26)43(68)56-32(19-25-7-2-1-3-8-25)42(67)53-30(15-16-36(49)61)41(66)57-33(21-37(50)62)44(69)58-34/h1-3,7-8,11-14,28-35,60H,4-6,9-10,15-24,47-48H2,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,67)(H,54,70)(H,55,64)(H,56,68)(H,57,66)(H,58,69)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
|
| Chemical Name |
(2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
|
| Synonyms |
Vasopressin-8-lysine; Lypressin; Diapid; Lypressine; Vasopressin; L-8; L 8; L8
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 100 mg/mL (~94.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9468 mL | 4.7339 mL | 9.4677 mL | |
| 5 mM | 0.1894 mL | 0.9468 mL | 1.8935 mL | |
| 10 mM | 0.0947 mL | 0.4734 mL | 0.9468 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
